Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029

Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029

Authoritative market research on cell therapy, gene therapy, and RNA therapy analyzing markets by disease type

Cell therapy and gene therapy represent a frontier in modern medicine, promising revolutionary treatments by treating the underlying genetic causes of disease and by genetically controlling the body's immune system. Recent years have seen an increase in new therapies and the pipeline indicates this trend will continue. A large range of therapeutic areas from oncology to cardiology have seen rapidly proliferating clinical trials. Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029 from Kalorama Information presents the market in segments that cover market estimates and forecasts, the development pipeline, and the competitive landscape of leading providers for each therapeutic area.

The report examines global developments in cell, gene, and RNA therapy markets for the select diseases and conditions in respective chapters, including principal products, trends in research and development, market breakdown of therapies, regional market revenues summary, and competitor summary.

The following therapeutic areas are covered in individual chapters with accompanying tables and figures:

• Oncology
• Neurology
• Musculoskeletal
• Dermatology
• Cardiology/non-oncology blood
• Other

Scope and Methodology

The report covers markets for cell therapies, gene therapies, and other various forms of RNA therapies. This report does not include RNA therapies for COVID-19 or mRNA vaccines for infectious diseases in its scope.

We are excluding mRNA-based products for infectious disease in this report because that area has largely been related to vaccines which is distinct; and partly due to the obscurity of the definition of cell and gene therapy. It will, however, be addressed in other Kalorama Information vaccine reports. RNA, antisense, and related types of therapies for other diseases are included due to the broad definition of gene therapy, including the use of nucleic acids to influence gene expression.

Note that this report also does not focus on cord blood products in the scope; these have technically been approved as cell therapy products by the FDA. There is some debate as to whether these are more akin to transplants.

Diseases are categorized into therapeutic areas primarily according to the general consensus but this is often an over-simplification; genetic diseases can become complicated to classify due to many systems being affected. In some cases, there may be inconsistencies. For example, a genetic mutation may affect the liver which results in excessive amounts of a certain molecule. This molecule then causes harm to the brain, and the condition is categorized as neurological despite the origin being in the liver.

Generally, the primary effects will first dictate the category, in combination with the condition’s cause. It can be case-by-case.

Information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company reports and literature; government documents and databases; research journals and reports; and general medical and business journals. Primary research methods include telephone interviews and email correspondence with company representatives, researchers and physicians. These interviews were conducted with the purpose of capturing the perspectives from industry participants on the market opportunity and current trends. This was the basis of the formulation of forecasting models and for confirming early findings related to market potential.

The market segments provide highlights and overviews of therapies, market estimates and forecasts, and competitive situations of leading providers. The report also includes information on cell and gene therapies in development and the impact these are expected to have on the market. Throughout the report, several market indicators, trends, and barriers are discussed.

Because gene therapies are currently not available in any wide capacity, there is little precedent upon which to base forecasts. Dollar figures represent the estimated global market for 2023 and expected market for 2029. Forecasts are provided through 2029 ,and the size of each market segment refers to manufacturers’ revenues.